At Novartis Oncology, our primary goal is to research and develop new methods to treat cancer better than is possible today. Every day, around the world, we’re exploring and pioneering new treatments that are likely to transform the way cancer is treated.

Our strong dedication to the needs of the patient can be seen in our corporate commitment to third party partnerships worldwide on patient education and disease-awareness campaigns.

Our goal is a comprehensive approach to the management of cancer. Novartis Oncology is committed to a wide range of medical education programs. We support oncology health care professionals in their endeavors to achieve a better understanding of cancer that may lead to innovative ideas and novel oncology therapies.

With over 2,000 associates around the world, Novartis Oncology provides the health care community, patients, and their loved ones with an unprecedented level of support-education, outreach, and financial assistance.

Learn more at Novartisoncology.com.

Find out more about our other breakthrough products by choosing a link below.

Femara is approved for use as adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer and extended adjuvant treatment of hormone dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.

Femara is also approved as a first-line treatment in postmenopausal women with hormone-dependent advanced breast cancer and for advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with antiestrogens.

Learn more at Femarainfo.com.

Zometa is indicated for patients with advanced malignancies involving bone which include multiple myeloma, prostate cancer, renal cancer, breast cancer, lung cancer, and other solid tumour types.

Learn more at Zometa.com.

SandostatinLAR (octreotide/IM injection) is indicated for the treatment of patients with acromegaly who are adequately controlled on s.c. treatment with Sandostatin, and in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective, and for treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours in whom symptoms are adequately controlled on s.c. treatment with Sandostatin.

Learn more at Sandostatin.com.

Exjade^® is a once-daily oral chelator for the treatment of chronic iron overload due to blood transfusions. It is formulated as tablets for dispersion to formulated as tablets drink in order to allow convenient administration to both adult and pediatric patients.

Learn more at Exjade.com.